Please assess the completion status of the following clinical trial:

Trial Title: SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed symptomatic Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) who have been treated with acenocoumarol, warfarin or SR34006 for six months~* Written informed consent~Exclusion Criteria:~* Legal age limitations (country specific)~* Indication for anticoagulation other than PE or DVT~* Creatinine clearance (CLcr) \<10 mL/min, severe hepatic disease, or bacterial endocarditis~* Participation in a pharmacotherapeutic study other than the Van Gogh-PE or DVT study within the prior 30 days~* Life expectancy \<3 months~* Patients in whom anticoagulation treatment for their index PE or DVT should be continued beyond 6 months~* Active bleeding or high risk for bleeding~* Uncontrolled hypertension: systolic blood pressure \>180 mm Hg or diastolic blood pressure \> 110 mm Hg~* Pregnancy, or childbearing potential without proper contraceptive measures, women who are breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).